D
David Sullivan
Researcher at Johns Hopkins University
Publications - 43
Citations - 1378
David Sullivan is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 5, co-authored 11 publications receiving 398 citations. Previous affiliations of David Sullivan include Johns Hopkins University School of Medicine.
Papers
More filters
Journal ArticleDOI
Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population.
Sabra L. Klein,Andrew Pekosz,Han-Sol Park,Rebecca L. Ursin,Janna R. Shapiro,Sarah E. Benner,Kirsten Littlefield,Swetha Kumar,Harnish Mukesh Naik,Michael J. Betenbaugh,Ruchee Shrestha,Annie A. Wu,Robert M. Hughes,Imani Burgess,Patricio Caturegli,Oliver Laeyendecker,Oliver Laeyendecker,Thomas C. Quinn,Thomas C. Quinn,David Sullivan,Shmuel Shoham,Andrew D. Redd,Andrew D. Redd,Evan M. Bloch,Arturo Casadevall,Aaron A.R. Tobian +25 more
TL;DR: Male sex, older age, and hospitalization with COVID-19 were associated with increased antibody responses across the serological assays, and IgG titers were greater than either IgM or IgA for S1, full length S, and S-RBD in the overall population.
letters-and-commentsDOI
Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant
Emi Takashita,Noriko Kinoshita,Seiya Yamayoshi,Yuko Sakai-Tagawa,Seiichiro Fujisaki,Mutsumi Ito,Kiyoko Iwatsuki-Horimoto,Shiho Chiba,Peter Halfmann,Hiroyuki Nagai,Makoto Saito,Eisuke Adachi,David Sullivan,Andrew Pekosz,Shinji Watanabe,Kenji Maeda,Masaki Imai,Hiroshi Yotsuyanagi,Hiroaki Mitsuya,Norio Ohmagari,Makoto Takeda,Hideki Hasegawa,Yoshihiro Kawaoka +22 more
Journal ArticleDOI
Comparative performance of five commercially available serologic assays to detect antibodies to SARS-CoV-2 and identify individuals with high neutralizing titers.
Eshan U. Patel,Eshan U. Patel,Evan M. Bloch,William Clarke,Yu Hsiang Hsieh,Denali Boon,Yolanda Eby,Reinaldo E Fernandez,Owen R Baker,Morgan Keruly,Charles S. Kirby,Ethan Klock,Kirsten Littlefield,Jernelle Miller,Haley A Schmidt,Philip Sullivan,Estelle Piwowar-Manning,Ruchee Shrestha,Andrew D. Redd,Andrew D. Redd,Richard E. Rothman,David Sullivan,Shmuel Shoham,Arturo Casadevall,Thomas C. Quinn,Thomas C. Quinn,Andrew Pekosz,Aaron A.R. Tobian,Oliver Laeyendecker,Oliver Laeyendecker +29 more
TL;DR: The diagnostic accuracy of five commercially available EIAs (Abbott, Euroimmun, EDI, ImmunoDiagnostics, and Roche) for detection of IgG or total antibodies to SARS-CoV-2 and neutralizing antibodies (nAbs) was evaluated.
Posted ContentDOI
Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population.
Sabra L. Klein,Andrew Pekosz,Han-Sol Park,Rebecca L. Ursin,Janna R. Shapiro,Sarah E. Benner,Kirsten Littlefield,Swetha Kumar,Harnish Mukesh Naik,Michael J. Betenbaugh,Ruchee Shrestha,Annie A. Wu,Robert M. Hughes,Imani Burgess,Patricio Caturegli,Oliver Laeyendecker,Oliver Laeyendecker,Thomas C. Quinn,Thomas C. Quinn,David Sullivan,Shmuel Shoham,Andrew D. Redd,Andrew D. Redd,Evan M. Bloch,Arturo Casadevall,Aaron A.R. Tobian +25 more
TL;DR: There was substantial heterogeneity in the antibody response among potential convalescent plasma donors, but sex, age and hospitalization emerged as factors that can be used to identify individuals with a high likelihood of having strong antiviral antibody levels.
Journal ArticleDOI
Early Outpatient Treatment for Covid-19 with Convalescent Plasma
David Sullivan,Kelly A. Gebo,Shmuel Shoham,Evan M. Bloch,Bryan Lau,Aarthi Shenoy,Giselle Mosnaim,Thomas J. Gniadek,Yuriko Fukuta,Bela Patel,Sonya L. Heath,Adam C. Levine,Barry Meisenberg,Emily S Spivak,Shweta Anjan,Moises A. Huaman,R. E. Blair,Judith S. Currier,James H. Paxton,Jonathan M. Gerber,Joann Petrini,Patrick B Broderick,W P Rausch,Marie Elena Cordisco,Jean M Hammel,B. Greenblatt,Valerie Cluzet,Daniel L. Cruser,Kevin Oei,M. S. Abinante,Laura L. Hammitt,Catherine G. Sutcliffe,Donald N. Forthal,Martin S. Zand,Edward R. Cachay,Jay S. Raval,Seble Kassaye,E C Foster,Michael Roth,Christi E. Marshall,Anusha Yarava,Karen Lane,Nichol McBee,Amy L. Gawad,Nicky Karlen,Atika Singh,Daniel E. Ford,Douglas A. Jabs,Lawrence J. Appel,David M. Shade,Stephan Ehrhardt,Sheriza N. Baksh,Oliver Laeyendecker,Andrew Pekosz,Sabra L. Klein,Arturo Casadevall,Aaron A.R. Tobian,Daniel F. Hanley +57 more
TL;DR: In participants with Covid-19, most of whom were unvaccinated, the administration of convalescent plasma within 9 days after the onset of symptoms reduced the risk of disease progression leading to hospitalization.